Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Evolus Inc (EOLS)
NASDAQ:EOLS
Evolus (EOLS) Stock Price & Analysis
330 Followers
EOLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.51 - $14.34
Previous Close$10.5
Volume458.91K
Average Volume (3M)436.00K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$65.57M
Total Debt (Recent Filing)$74.51M
Price to Earnings (P/E)-7.4
Beta0.34
Next EarningsMar 01, 2023
EPS Estimate-$0.18
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$16.60
EPS (TTM)-1.42
Shares Outstanding56,246,570
R-Squared0.05
Standard Deviation0.43
10 Day Avg. Volume524,176
30 Day Avg. Volume436,005
Price to Book (P/B)-14.40
Price to Sales (P/S)5.92
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-7.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside63.55% Upside
Rating ConsensusStrong Buy
Alpha0.03
Number of Analyst Covering5
Evolus News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EOLS FAQ
What was Evolus’s price range in the past 12 months?
Evolus lowest stock price was $6.51 and its highest was $14.34 in the past 12 months.
What is Evolus’s market cap?
Currently, no data Available
When is Evolus’s upcoming earnings report date?
Evolus’s upcoming earnings report date is Mar 01, 2023 which is in 33 days.
How were Evolus’s earnings last quarter?
Evolus released its earnings results on Nov 08, 2022. The company reported -$0.278 earnings per share for the quarter, beating the consensus estimate of -$0.308 by $0.03.
Is Evolus overvalued?
According to Wall Street analysts Evolus’s price is currently Undervalued.
Does Evolus pay dividends?
Evolus does not currently pay dividends.
What is Evolus’s EPS estimate?
Evolus’s EPS estimate is -$0.18.
How many shares outstanding does Evolus have?
Evolus has 56,246,570 shares outstanding.
What happened to Evolus’s price movement after its last earnings report?
Evolus reported an EPS of -$0.278 in its last earnings report, beating expectations of -$0.308. Following the earnings report the stock price went down -9.126%.
Which hedge fund is a major shareholder of Evolus?
Among the largest hedge funds holding Evolus’s share is Deerfield Management Company, LP. It holds Evolus’s shares valued at 43M.
---
Evolus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.60
$16.60
Blogger Sentiment
Bullish
EOLS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.8%
Last 30 Days ▲ 12.6%
Last 30 Days ▲ 12.6%
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
59.33%
12-Months-Change
Fundamentals
Return on Equity
-125.45%
Trailing 12-Months
Asset Growth
-10.45%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Evolus Inc
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.
---
Bakhu Holdings
―
NGM Biopharmaceuticals
―
Tarsus Pharmaceuticals
―
Rani Therapeutics Holdings
―
---